Status and phase
Conditions
Treatments
About
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age ≥18 years on the day of signing informed consent.
Histologically confirmed diagnosis of cHL.
Disease status as defined as.
Must have ECOG performance status of 0 or 1
At least one bi-dimensional measurable lesion with minimum measurement of > 15 mm in the longest diameter.
Toxicities related to prior therapy must have returned to Grade 1 or less, except for alopecia.
Use of an effective means of contraception for women of childbearing potential and men with partners of childbearing potential
Provide written informed consent prior to any study-specific screening procedures.
Willingness and capability to comply with the requirements of the study.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
2 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal